New Triple-Threat drug combo tested to control aggressive blood cancer
NCT ID NCT06561880
Summary
This study is testing a combination of three drugs (gilteritinib, venetoclax, and azacitidine) for adults and teens newly diagnosed with a fast-growing blood cancer called AML, who have a specific genetic change (FLT3 mutation) and are healthy enough for strong treatment. The main goals are to find the safest dose of gilteritinib in this combination and to see how well the three drugs work together to control the cancer and keep it from coming back. Researchers will closely monitor patients' response using sensitive tests that look for tiny amounts of leftover cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.